Central venous catheter

First U.S. Implantation of VasQ™ Since FDA De Novo was Granted

Retrieved on: 
Tuesday, January 16, 2024
Mortality, Patient, Fistula, Gilon, Health, Risk, CVC, COVID-19, Lamination, Infection, Central venous catheter, Arteriovenous fistula, Medical imaging

SPARTANBURG, S.C., Jan. 16, 2024 /PRNewswire/ -- The first U.S. implantation of VasQ™ since FDA De Novo was granted was successfully performed by Dr. Ari Kramer, Director and principal surgeon of Vascular Access Surgery at Spartanburg Regional Hospital in Spartanburg, SC.

Key Points: 
  • SPARTANBURG, S.C., Jan. 16, 2024 /PRNewswire/ -- The first U.S. implantation of VasQ™ since FDA De Novo was granted was successfully performed by Dr. Ari Kramer, Director and principal surgeon of Vascular Access Surgery at Spartanburg Regional Hospital in Spartanburg, SC.
  • VasQ is a nitinol-based external support device for the artery and vein anastomosis during the surgical creation of an arteriovenous fistula to promote maturation into a functional access for hemodialysis.
  • The device was designed to provide structural reinforcement of the mobilized vessels and guides a more stable arterial flow profile as it transitions into the vein.
  • Creating more functional fistulas with the assistance of a device like VasQ should help to reduce the CVC exposure for this patient population.

Global Vascular Access Devices (MedSuite) Market Size, Share & Trends Analysis 2024-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 17, 2023
Medical Supplies, Medical Devices, Health, Surgery, Cardiology, Biotechnology, PICC, Teleflex, Central venous catheter, Acquisition, Research, BD (company), Risk, Catheter, Peripherally inserted central catheter, CVC, Growth, Bard (company), Medical imaging, Medical device

The "Global Vascular Access Devices Market Size, Share & Trends Analysis 2024-2030 - MedSuite" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Vascular Access Devices Market Size, Share & Trends Analysis 2024-2030 - MedSuite" report has been added to ResearchAndMarkets.com's offering.
  • While this MedSuite report provides a comprehensive overview of the Global Vascular Access Devices market, you also have the option to access each market segment individually as stand-alone MedCore reports.
  • The global vascular access device market is on the brink of substantial expansion, and long-term devices like implantable ports, CVCs, and PICCs are emerging as the primary drivers of this growth.
  • In 2023, Becton Dickinson continued to maintain its dominant position as the leader in the global vascular access device and accessories market.

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Retrieved on: 
Thursday, November 30, 2023
PICC, NYSE, BDX, Nursing, Patient, Central venous catheter, System, Workflow, Standard of care, Medical imaging

FRANKLIN LAKES, N.J., Nov. 30, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.

Key Points: 
  • FRANKLIN LAKES, N.J., Nov. 30, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.
  • The SiteRite™ 9 Ultrasound System is an all-in-one system designed with a user-friendly experience on an updated 15.6-inch touch screen with enhanced image quality that provides industry-leading catheter placement tools and technologies to support clinicians during the vascular access device insertion process.
  • Additional system capabilities include patient data look up with information capture, auto-filling capabilities and records transfer to help support clinician workflow.
  • As a global leader in vascular access solutions, BD is committed to advancing the standard of care for patients and health care providers.

United States Medical Sterilizers Market Insights Report 2023-2028: Next-Gen Sterilization Methods on the Rise, Transforming the Landscape - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 23, 2023
Hospitals, Health, Medical Supplies, Medical Devices, Ethylene oxide, HAI, Infection, CLABSI, H2O2, Hygiene, Sterilization, CDC, Death, Hospital, Hydrogen peroxide, Patient, Ozone, Central venous catheter, ClO2, Safety, Peracetic acid, Medical device

The "US Medical Sterilizers Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Medical Sterilizers Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • US Medical Sterilizers Market is projected to reach a value of $3.43 billion by 2028 from $2.13 billion in 2022, growing at a CAGR of 8.3%
    This report provides an in-depth analysis of the complete US Medical Sterilizers market.
  • The Medical Sterilizers market is one of the growing markets in the US.
  • The rise of new products like printed organs and semi-synthetic implants are demanding unique sterilization methods in the market.

Asep Inc. Obtains Exclusive Worldwide License from the University of British Columbia for Ground-breaking Medical Device Coating Technology

Retrieved on: 
Wednesday, August 2, 2023
Agreement, Infection, Contact, Minority, ASEP, Catheter, CSE, University, MI, Diabetes, CVC Capital Partners, CVC, FSE, International finance, USD, Centers for Disease Control and Prevention, Titanium, CDC, End-user license agreement, Incidence, Good, PMA, Central venous catheter, Hospital, Prosthesis, Patient, National Healthcareer Association, Patent, Stent, Growth, Conditional sentence, License, FDA, UBC, Fungal infection, Glass, Multilateral, Acquisition, Safety, Pharmaceutical industry, Medical device, Security (finance), Research

Catheters are an excellent example of medical instruments that can cause serious infections.

Key Points: 
  • Catheters are an excellent example of medical instruments that can cause serious infections.
  • According to the Center for Disease Control and Prevention (CDC), approximately 90% of serious infections caused by catheters are associated with central venous catheters (CVCs).
  • UBC and the non-waiving inventors of the Technology will collectively own the remaining 12% of the issued and outstanding shares of SafeCoat in consideration for the exclusive license grant.
  • Dr. Robert E. W. Hancock, Founder and CEO of Asep Inc., is one of the four non-waiving inventors of the SafeCoat Technology.

Asep Inc. Obtains Exclusive Worldwide License from the University of British Columbia for Ground-breaking Medical Device Coating Technology

Retrieved on: 
Tuesday, August 1, 2023
Agreement, Infection, Contact, Minority, ASEP, Catheter, CSE, University, MI, Diabetes, CVC Capital Partners, CVC, FSE, International finance, USD, Centers for Disease Control and Prevention, Titanium, CDC, End-user license agreement, Incidence, Good, PMA, Central venous catheter, Hospital, Prosthesis, Patient, National Healthcareer Association, Patent, Stent, Growth, Conditional sentence, License, FDA, UBC, Fungal infection, Glass, Multilateral, Acquisition, Safety, Pharmaceutical industry, Medical device, Security (finance), Research

Catheters are an excellent example of medical instruments that can cause serious infections.

Key Points: 
  • Catheters are an excellent example of medical instruments that can cause serious infections.
  • According to the Center for Disease Control and Prevention (CDC), approximately 90% of serious infections caused by catheters are associated with central venous catheters (CVCs).
  • UBC and the non-waiving inventors of the Technology will collectively own the remaining 12% of the issued and outstanding shares of SafeCoat in consideration for the exclusive license grant.
  • Dr. Robert E. W. Hancock, Founder and CEO of Asep Inc., is one of the four non-waiving inventors of the SafeCoat Technology.

India Drug Delivery Procedures Databook 2015-2023 with Focus on Procedures Using Central Venous Catheters and Procedures Using Implantable Ports - Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 30, 2023
Health, Pharmaceutical, Growth, Central venous catheter, Procedure, Medical device, Birth control

The "India Drug Delivery Procedures Count by Segments (Procedures Using Central Venous Catheters and Procedures Using Implantable Ports) and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India Drug Delivery Procedures Count by Segments (Procedures Using Central Venous Catheters and Procedures Using Implantable Ports) and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • 'India Drug Delivery Procedures Outlook to 2030" is a comprehensive databook report, covering key procedures data on the India Drug Delivery Procedures.
  • The databook report provides procedure volumes within segments - Procedures Using Central Venous Catheters and Procedures Using Implantable Ports.
  • The India Drug Delivery Procedures report provides key information and data on Procedure volume data for Drug Delivery Procedures related to the country.

OBVIUS Robotics™ Announces Completion of Successful First-In-Human Cases

Retrieved on: 
Thursday, June 8, 2023
ER, Hospital, Democratization of technology, CVC, Sale, Blood, Femoral vein, Central venous catheter, MD, Patient, Robotics, Sanatorio de Muñecos, Mortality, ICU

WESTON, Fla., June 8, 2023 /PRNewswire/ -- Obvius Robotics, Inc., a medical device company that has developed an innovative technology platform for performing percutaneous access, today announced the successful completion of its first human cases.

Key Points: 
  • WESTON, Fla., June 8, 2023 /PRNewswire/ -- Obvius Robotics, Inc., a medical device company that has developed an innovative technology platform for performing percutaneous access, today announced the successful completion of its first human cases.
  • The cases were conducted at The Sanatorio Italiano in Asuncion, Paraguay under the supervision of principle investigator Adrian Ebner, MD.
  • The clinical team successfully placed central venous catheters (CVC) during 19 procedures using the company's CERTA Access System™.
  • "This successful first-in-human study comes after two years of rigorous work proving the design and value proposition in a preclinical setting," stated Russell Seiber, CEO and President of Obvius Robotics.

Teleflex Awarded Agreements with Premier, Inc.

Retrieved on: 
Thursday, June 1, 2023
Infection, Multisourcing, CLABSI, CVC, Gram-negative bacteria, TFX, Patient Centered Primary Care Collaborative, Fungus, Thrombosis, Hospital, Patient, Risk, Central venous catheter, Premier, NYSE, Birth control, Teleflex

WAYNE, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded two group purchasing agreements with Premier, Inc.

Key Points: 
  • WAYNE, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded two group purchasing agreements with Premier, Inc.
  • Effective July 1st, 2023, the new agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex’s Central Venous and Arterial Vascular Access products.
  • Premier has awarded Teleflex a national agreement for Hemodynamic Monitoring Products and Accessories, a national agreement for Central Venous Access, a Sole Source for AscenDrive Central Venous Access, and a Sole Source for SURPASS Central Venous Access.
  • “Teleflex strives to deliver vascular access products that are designed to benefit both clinicians and patients, while helping to protect against vascular access related complications like infection and thrombosis,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular.

Cormedix Inc. Announces Presentation at Conference Showing Mortality Risk and Complications in Patients Experiencing Catheter Related Blood Stream Infections

Retrieved on: 
Tuesday, December 6, 2022
New chemical entity, CMO, Fast Track, Incidence, Marketing, CMS, Myocardial infarction, Kidney failure, CRL, Moyamoya disease, Urinary tract infection, Infection, LTCS, Research, Investment, Pharmacy management system, Stroke, ASHP, CVC, FDA, HD, New Drug Application, Female, Central venous catheter, Medicare, Pneumonia, Society, Heart failure, Mortality, Gangrene, QIDP, Endpoint security, Trial of the century, IP, Heparin, API, Patient, NTAP, PVD, Peripheral artery disease, Disease, OP, NDA, Cancer, Risk, Pharmaceutical industry, Health insurance, Medical device, HF, Coronavirus

The conclusions from this retrospective study further underscore the significant mortality risk and long-term complications associated with catheter-related bloodstream infections (CRBSIs).

Key Points: 
  • The conclusions from this retrospective study further underscore the significant mortality risk and long-term complications associated with catheter-related bloodstream infections (CRBSIs).
  • The data show that of the 51,161 CVC-HD patients studied, approximately 33% of patients initiated on HD with a CVC experience a CRBSI.
  • CorMedix remains steadfast in our efforts to obtain marketing authorization and bring DefenCath to patients in 2023.”
    The abstract accepted for presentation is included below.
  • To date, CRBSIs remain a preventable complication of CVC-dependent HD (CVC-HD) with high morbidity and mortality resulting from long-term complications (LTCs).